insulin drugs glp 1 receptor agaonist market Glucagon-Like Peptide (GLP-1) Agonist Size & Share 2032 GLP-1 Receptor Agonist Market Size

39.7% of patients achieved more than 25% weight loss compared to 0.3% on lifestyle changes alone

They already make the most potent weight-loss medication out there, Low Wang said, referring to Zepbound and Mounjaro

4 Approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors

Published in 2019, it did not show superiority in reducing MACE, but it provided valuable evidence regarding the safety and oral delivery of GLP-1 receptor agonists, expanding treatment options for patients with T2D (43)

In addition, the drug combination also had no effect on the intestinal microbiome in elderly patients with T2DM, but there was an increase in the percentage of bacteria of the genus Alistipes

GLP-1 medications slow gastric motility, which can affect bowel function